Bausch Health Companies (BHC) EBITDA Margin (2009 - 2026)
Bausch Health Companies (BHC) posted EBITDA Margin of 25.95% for Q2 2026, up 168.94% sequentially from 37.64% in Q1 2026, and up 840.0% YoY from 2.76% in Q2 2025.
Bausch Health Companies (BHC) EBITDA Margin (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported EBITDA Margin for 18 years, with the latest figure at 25.95% in Q2 2026.
- Quarterly EBITDA Margin rose 840.0% year-over-year to 25.95% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 8.14% (down 805.0% YoY) and the FY2025 annual result came in at 17.66%, up 160.0% from the prior year.
- EBITDA Margin rose to 25.95% in Q2 2026 per BHC's latest filing, from 37.64% in the prior quarter.
- Over five years, EBITDA Margin peaked at 25.95% in Q2 2026 and troughed at 37.64% in Q1 2026.
- A 5-year average of 10.54% and a median of 13.96% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2026: EBITDA Margin soared 2579 bps in 2023, then plunged 4986 bps in 2026.
- Over 5 years, EBITDA Margin stood at 10.76% in 2022, then soared by 240 bps to 15.03% in 2023, then surged by 45 bps to 21.81% in 2024, then decreased by 22 bps to 16.95% in 2025, then surged by 53 bps to 25.95% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 25.95%, 37.64%, and 16.95% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Bausch Health Companies | 2.57 Bn | 734.50 Mn | 2.10 Bn | 25.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.95% |
| Mar 31, 2026 | -37.64% |
| Dec 31, 2025 | 16.95% |
| Sep 30, 2025 | 23.09% |
| Jun 30, 2025 | 17.55% |
| Mar 31, 2025 | 12.22% |
| Dec 31, 2024 | 21.81% |
| Sep 30, 2024 | 12.67% |
| Jun 30, 2024 | 16.19% |
| Mar 31, 2024 | 13.05% |
| Dec 31, 2023 | 15.03% |
| Sep 30, 2023 | 0.63% |
| Jun 30, 2023 | 19.01% |
| Mar 31, 2023 | 9.00% |
| Dec 31, 2022 | -10.76% |
| Sep 30, 2022 | 11.93% |
| Jun 30, 2022 | 8.19% |
| Mar 31, 2022 | 14.86% |
| Dec 31, 2021 | 5.07% |
| Sep 30, 2021 | 27.19% |